Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 8Gastrointestinal 3Tumor-Agnostic 2CNS 2Sarcoma 1Myeloid 1

Conditions

Cholangiocarcinoma 3Glioma 1Chondrosarcoma 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × ivosidenib × Gastrointestinal × Clear all
NCT05876754 2026-02-19

ProvIDHe

Servier

Phase 3 Recruiting
220 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Servier

Phase 1 Completed
174 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT02989857 2024-08-20

ClarIDHy

Servier

Phase 3 Completed
187 enrolled 34 charts 1 FDA
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡